

## 2016 Fall Alliance Group Meeting Committee Agenda

<b>Committee</b>	LEUKEMIA / LEUKEMIA CORRELATIVE SCIENCES	
<b>Meeting Date / Time</b>	Saturday, November 5, 2016: 8:00 a.m.- 12:00 noon	
<b>Chair(s)</b>	Richard M. Stone, MD; John C. Byrd, MD	
<b>Vice Chair(s)</b>	Guido Marcucci MD ( LC), MD, Tom Shea, MD (LC), Wendy Stock, MD, Ph ( LC/LCS)	
<b>Title/Speaker</b>	<b>Introduction/Moment of Silence in Memory of Dr. Sargent</b>	
	Richard Stone MD	(8:00 – 8:10)
<b>Title/Speaker</b>	<b>Update: Alliance U10 Correlative Sciences</b>	
	Clara Bloomfield MD	(8:10 – 8:20)
<b>Title/Speaker</b>	<b>Statistics and Data Management</b>	
	Sumithra Mandrekar PhD et al	(8:20 – 8:30)
<b>Title/Speaker</b>	<b>Cyclin D2 in CBF AML</b>	
	Ann-Kathrin Eisfeld MD, PhD	(8:30-8:45)
<b>Title/Speaker</b>	<b>Oncoprint of AML</b>	
	Ann-Kathrin Eisfeld MD, PhD	(8:45-9:00)
<b>Title/Speaker</b>	<b>Long Non-Coding RNAs in AML: Prognostic and Functional Role</b>	
	Vivien Yin PhD	(9:00 – 9:15)
<b>Title/Speaker</b>	<b>Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia</b>	
	Dimitrios Papaioannou MD, PhD	(9:15 – 9:30)
<b>Title/Speaker</b>	<b>CALGB 10404: Initial Results of Randomized Trial</b>	
	John Byrd MD	(9:30 – 9:45)

## 2016 Fall Alliance Group Meeting Committee Agenda

Protocol Review				
Category	Study Title	Study Number	Study Chair	Presenter's Name
Active	Chemo +/- blinatumumab in middle aged adults with pre-B-ALL	E1910	M . Litzow MD M. Wieduwilt MD, (A)	M. Wieduwilt MD(9:45-9:50)
In Development	PH+ ALL working groups concepts, incl S0805 and C01701			K. Jamieson MD (9:50 – 10:00)
In Development	Aya chemo ± inotuzumab in younger adults with B cell ALL	A041501	D. DeAngelo MD	W. Stock MD(10:00 - 10:10)
Active	Blinatumumamab plus POMP in PH- ALL, age >70	S1318	A.Advani MD M. Wieduwilt MD (A)	M. Wieduwilt MD (10:10-10:15)
In Development	Dual Ab rx of relapsed Ph-ALL		M. Wieduwilt MD	M. Wieduwilt MD (10:15-10:30)
Recently Closed	FCR v ibrutinib in younger CLL	E1910	T. Shanafelt J. Barrientos (A)	J. Barrientos (Notation only)
Recently Closed	Ibrutinib v ibrutinib/rituximab v bendamustine/rituximab in older adults with untreated CLL	A041202	J. Woyach MD	J. Woyach MD (Notation only)
In Development	Novel agents trial for IgVlt mutant CLL		J. Brown MD, PhD	J. Brown MD, PhD (10:30-10:45)
Concept Proposal	Novel Targeted Therapy in Elderly CLL			J. Woyach MD, PhD (10:45-11:00)
Active	Revlimid alone +/- Procrit in low or inter-1 risk MDS & symp anem	E2905	A. List MD	Notation Only
In Development	Older adult 'unfit' SWOG trial			H. Klepin MD (11:00 - 11:15)
In Development	7+ 3 + novel agent in elderly AML		G. Uy MD, PhD	G. Uy MD , PhD (11:15 – 11:30)
Concept Proposal—Alliance Foundation	Standard therapy +/- entospletinib in young NPM1+ AML			A Mims MD(11:30-11:45)
Concept	Entospletinib in MDS			A Walker MD (11:45-

## 2016 Fall Alliance Group Meeting Committee Agenda

Proposal—Alliance Foundation				Noon)
---------------------------------	--	--	--	-------